Advances in ostheochlast biology: The osteoprotegerin-RANK ligand system;Avances en el conocimiento de la biología del osteoclasto: El sistema osteoprotegerina-ligando del RANK

Medicina Clinica

Volumn 122, Issue 2, 2004, Pages 75-77

  Muñoz Torres, Manuel ^a,b   De La Higuera Lopez Frias, Magdalena ^a   Fernández García, Diego ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b NONE   (Spain)

Author keywords

Osteoclast; Osteoporosis; Osteoprotegerin; RANK ligand

Indexed keywords

DECOY RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ALBERS SCHOENBERG DISEASE; ANIMAL MODEL; BONE MATRIX; BONE METABOLISM; CELL ACTIVATION; CELL DIFFERENTIATION; METABOLIC BONE DISEASE; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PARACRINE SIGNALING; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION;

EID: 1142298952     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(04)74146-9     Document Type: Review

References (20)

1. Raisz LG, Rodan GA. Pathogenesis of osteoporosis. Endocrinol Metab Clin North Am 2003;32:15-24.
2. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-14.
3. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
4. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-8.
5. Hofbauer LC, Heufelder AE. The role of the receptor activator of nuclear factor-kB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic diseases. J Clin Endocrinol Metab 2000;85:2355-63.
6. Khosla S. The OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5.
7. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000;157:435-48.
8. Aubin JE, Bonnelye E. Osteprotegerin and its ligand: a new paradigm for the regulation of osteoclastogenesis and bone resorption. Osteopor Int 2000;11:905-13.
9. Hofbauer LC, Khosla S, Dunston CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12.
10. McLean W, Olsen BR. Mouse models of abnormal skeletal development and homeostasis. Trends Genetics 2001;17:S38-S43.
11. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8.
12. Lories RJ, Luyten FP. Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. Clin Rheumatol 2001;20:3-9.
13. Zaidi M, Blair HC, Moonga BS, Abe E, Huang CL. Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J Bone Miner Res 2003;18:599-609.
14. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549-53.
15. Kong Y-Y, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
16. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhace T-cell growth and dendritic-cell function. Nature 1997;390:175-9.
17. Bord S, Ireland DC, Beavan SR, Compston JE. The effects of estrogen on osteoprotegerin, RANKL and estrogen receptor expression in human osteoblasts. Bone 2003;32:136-41.
18. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgomik MN, McAlister WH, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002;347:175-84.
19. Bekker PJ, Holloway D, Nakanishi A, Arrighi HM, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001;16:348-60.
20. 3-induced, NF-kappa-B dependent survival factor for endothelial cells. J Biol Chem 2000;275:20959-62.